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Abstract A novel competition dialysis method was used to study
the structural selectivity of the nucleic acid binding of NB-506, a
promising indolocarbazole anticancer agent. A pronounced
preference for NB-506 binding to the DNA triplex poly
[dA]:(poly[dT])2 was observed among potential binding to 12
different nucleic acid structures and sequences. Structures
included in the assay ranged from single-stranded DNA, through
a variety of right-handed DNA duplexes, to multistranded triplex
and tetraplex forms. RNA and left-handed Z DNA were also
included in the assay. The preferential binding to triplex was
confirmed by UV melting experiments. The novel and unexpected
structural selectivity shown by NB-506 may arise from a
complementary shape between its extended aromatic ring system
and the planar triplex stack.
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1. Introduction
DNA intercalating agents have a long history in the treat-
ment of human disease and of cancer in particular [1]. For
over three decades the intercalating anthracycline antibiotics
doxorubicin and daunorubicin have been the lead clinical
drugs of choice against a number of neoplastic diseases. Acti-
nomycin, another intercalating antibiotic discovered in the
early 1950s, continues to be used extensively worldwide as
an antitumor agent. Mitoxantrone, which is particularly use-
ful for the treatment of breast cancers, is also a typical DNA-
intercalating agent. Other potent anticancer agents that inter-
calate into DNA include amsacrine, bisantrene, amona¢de,
nogalamycin, and porphyrins [2].
In recent years, novel DNA-intercalating agents endowed
with potent anticancer activities have been discovered. One of
the most promising series is the indolocarbazoles, typi¢ed by
the antitumor antibiotic BE-13793C produced by a strain of
actinomycetes [3] and its glycosylated analog rebeccamycin
isolated from a culture of Saccharotrix aerocolonigenes [4].
Water-soluble derivatives of these two antibiotics have been
developed recently. The most active compound in the series is
the compound 6-N-formylamino-12,13-dihydro-1,11-dihy-
droxy-13-(-D-glucopyranosyl)-5H-indolo[2,3-a]pyrrolo-[3,4-c]-
carbazole-5,7-(6H)-dione (NB-506, Fig. 1) [5]. The carbohy-
drate moiety of NB-506 and related derivatives not only
signi¢cantly increases the water-solubility of the drugs, but
also enhances their interaction with double stranded DNA
[6,7]. NB-506 has shown remarkable e⁄cacy against a variety
of human tumor xenografts, including lung and colon cancers,
and metastatic cells [5,8^10]. Recently the drug has entered
clinical trials. The results of the ¢rst phase I study are prom-
ising and exciting clinical developments for this compound are
expected in the near future [11].
The exceptional antitumor activity of NB-506 is attributed
to the capacity of the drug to intercalate into DNA and to
inhibit topoisomerase I [12]. NB-506 converts topoisomerase I
into a cell poison by trapping covalent DNA-topoisomerase I
complexes, thereby enhancing the formation of persistent
DNA breaks responsible for cell death. In that respect, the
mechanism of action of NB-506 closely resembles that of an-
other series of antitumor agents recently introduced in the
clinic, the camptothecins [13]. Other aspects of the mechanism
of action of NB-506, including its interaction with nucleic
acids, have not been characterized in any detail. Recently
we showed that NB-506 intercalates preferentially into GC-
rich sequences of B-DNA [14]. But apart from B-DNA, it is
not known if NB-506 can interact with other nucleic acids
structures such as single strand polymers, RNA, Z DNA,
DNA triple helices, and tetraplexes. This issue is addressed
here.
DNA is a highly adaptable molecule that can exist within
cells in a variety of conformations and structures not re-
stricted to the canonical Watson^Crick B-form. DNA mainly
exists as an antiparallel double-stranded helix in the cell, but it
can form triplex and quadruplex structures into which an
intercalating drug like NB-506 may bind. In the past few
years, a variety of triplex-selective intercalators have been de-
signed (e.g. BePI and derivatives, naphthyl quinolines, anthra-
quinone) [15,16] and more recently a few intercalating agents
capable of interacting with G-quadruplexes have been re-
ported [17^19]. NB-506, which possesses a large six-ring pla-
nar chromophore, could stack over base triplets and tetrads,
in addition to interacting with duplex DNA.
In most drug^DNA binding studies, the interaction of the
test drug with only one or two DNA substrates are studied,
due to the labor involved in conducting proper equilibrium
binding studies. To better understand how small molecules
can interact selectively with di¡erent nucleic acids structures,
ideally one would like to compare the binding of the drug to a
variety of nucleic acid structures simultaneously. A suitable
method for this purpose was recently devised, a competition
dialysis method that provides a rigorous, thermodynamically
sound indication of structural selectivity [20].
The present competition dialysis method evolved from a
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technique ¢rst used by Mueller and Crothers to explore the
base speci¢city of DNA intercalation reactions [21,22]. In the
new application [20], we have devised a suitable bu¡er in
which a variety of DNA and RNA structures are stable. In
the competition dialysis experiment, equal volumes of these
DNA samples (at identical concentrations) are dialyzed
against a common dialysate solution containing the ligand
under study. After equilibrium dialysis is attained (usually in
24 h or less), the amount of ligand bound to each DNA is
measured by absorbance. Since all of the DNA samples are in
equilibrium with the same free ligand concentration, the
amount of bound ligand is directly proportional to the asso-
ciation constant for ligand binding to a particular structure.
Comparison of the amount of bound ligand to each DNA
sample provides a rapid, thermodynamically rigorous indica-
tion of the structural selectivity of the ligand under study. The
advantages of the new method are many, including its speed,
its sound thermodynamic basis, and its relative ease.
The competition dialysis method has been successfully ap-
plied to determine the structural speci¢city of NB-506. This
novel approach has allowed us to monitor simultaneously the
binding of the indolocarbazole derivative to a variety of DNA
substrates ranging from single stranded synthetic polymers to
much more complex three- and four-stranded structures. Un-
expectedly, we discovered that NB-506 exhibits a remarkable
preference for the poly dA:(poly dT)2 triple helical polymer.
The triplex-stabilizing e¡ect of NB-506 was con¢rmed by
thermal denaturation studies. So far as we know, this is the
¢rst example of an uncharged intercalating agent shown to
stabilize triplex DNA.
2. Materials and methods
2.1. Drug
Dr. Tomoko Yoshinari (Banyu Pharmaceuticals, Japan) kindly pro-
vided a sample of NB-506. The chemical synthesis of the drug has
been reported [23]. The drug was ¢rst dissolved in dimethylsulfoxide
(DMSO) at 10 mM and then further diluted with water. The stock
solution was kept at 320‡C and freshly diluted to the desired con-
centration immediately prior to use.
2.2. Nucleic acids
DNA samples from Clostridium perfringens (Lot 86H4010), Micro-
coccus lysodeikticus (Lot 108H4017) and calf thymus (Lot 95H9526)
were purchased from Sigma (St. Louis, MO, USA) and were soni-
cated, phenol-extracted and puri¢ed as previously described [24]. Poly
dA (Lot 7067836021), poly dT (Lot 8017834021), poly dA:poly dT
(Lot 8097860021), poly (dAdT) (Lot 8067870021) and poly (dGdC)
(Lot 8107910021) were purchased from Pharmacia Biotech (Piscat-
away, NJ, USA). Poly A:poly U (Lot 10H4005) was purchased
from Sigma (St. Louis, MO, USA). Synthetic polynucleotides were
used without further puri¢cation. Solutions containing the poly dA:
(poly dT)2 triplex were prepared by mixing poly dA:poly dT with
poly dT in a 1:1 mol ratio, heating to 90‡C, and slowly cooling to
room temperature. Tetraplex DNA ([5P T2G20T2]4) was prepared by
heating [5P T2G20T2] (from Research Genetics, SW Huntsville, AL,
USA) to 90‡C for 2 min, slowly cooling to room temperature, and
then equilibrating for 48 h at 4‡C before use. Left-handed, Z DNA
was prepared by bromination of poly (dGdC) as previously described
[25].
2.3. Competition dialysis assay
Full details of the competition dialysis assay may be found in [20].
A brief description follows. For each competition dialysis assay, 200
ml of the dialysate solution containing 1 WM ligand concentration was
placed into a beaker. A volume of 0.5 ml of each of the nucleic acid
samples was pipetted into a separate 0.5 ml Spectro/Por Dis-
poDialyzer0 unit (Spectrum, Laguna Hills, CA, USA). All nucleic
acid samples were at an identical concentration of 75 WM. (Nucleic
acid concentration is expressed in terms of the monomeric unit for
each polymer, i.e. nucleotides for single strands, base pairs for duplex
forms, triplets for the triplex and tetrads for the tetraplex). All 12
dialysis units were then placed in the beaker containing the dialysate
solution. The beaker was covered with para¢lm, wrapped in foil, and
allowed to equilibrate with continuous stirring for 24 h at room tem-
perature (20^22‡C). At the end of the equilibration period, DNA
samples were carefully removed to microfuge tubes, and were made
to a ¢nal concentration of 1% (w/v) sodium dodecyl sulfate (SDS) by
the addition of appropriate volumes of a 10% (w/v) stock solution.
The total concentration of NB-506 (Ct) within each dialysis unit was
then determined spectrophotometrically using an extinction coe⁄cient
of 14 000 M31 cm31 (at 330 nm). An appropriate correction for the
slight dilution of the sample resulting from the addition of the stock
SDS solution was made. The free ligand concentration (Cf ) was de-
termined spectrophotometrically using an aliquot of the dialysate so-
lution, although its concentration usually did not vary appreciable
from the initial 1 WM concentration. The amount of bound drug
was determined by di¡erence, Cb = Ct3Cf .
2.4. UV melting studies
UV DNA melting curves were determined using a Cary 3E UV/
Visible spectrophotometer (Varian, Palo Alto, CA, USA), equipped
with a thermoelectric temperature controller. Solutions of DNA (¢nal
concentration 2.0U1035 M) were prepared by direct mixing with ali-
quots from ligand stock solution, followed by incubation for 12 h at
24‡C to ensure equilibration. Samples were heated at a rate of 1‡C
min31, while continuously monitoring the absorbance at 260 nm.
Primary data were transferred to the graphics program Origin (Micro-
cal, Northampton, MA, USA) for plotting and analysis.
3. Results and discussion
Fig. 1 shows the results obtained from the competition
dialysis procedure. Data are presented as a bar graph, in
which the amount of NB-506 bound to each nucleic acid
sample is plotted. The striking result to emerge is the strong
preference of NB-506 for the triplex DNA sample included in
the assay, poly dA:(poly dT)2. Under the ionic conditions of
this assay, NB-506 binding to triplex is at least four-fold
greater than to any other nucleic acid conformation, with
duplex M. lysodeikticus DNA representing the next most pre-
ferred form. The amount bound plotted in Fig. 1 is directly
proportional to the binding constants for the interaction of
NB-506 with the various nucleic acid structures studied. In the
competition dialysis experiment, all nucleic acid structures are
maintained at identical concentrations. Since all nucleic acid
structures in the assay are in equilibrium with the same free
ligand concentration, the amount bound depends only on the
binding constant. We previously measured the binding con-
stant (K) for the interaction of NB-506 with calf thymus DNA
by £uorescence titration under the same bu¡er conditions as
used in the competition dialysis experiment, and found
K = 1.5U104 M31 [14]. From the data obtained in Fig. 1,
Kapp = 0.8U104 M31 may be calculated for the binding of
NB-506 to calf thymus DNA, a value in reasonable agreement
with the more complete titration data.
The pronounced preference of NB-506 for triplex DNA was
con¢rmed by the UV melting studies shown in Fig. 2. In the
absence of NB-506, melting of poly dA:(poly dT)2 is biphasic.
The triplexCduplex+poly dT transition is centered at
Tm = 42.5‡C, with melting of the remaining poly dA:poly dT
duplex at Tm = 75.2‡C. Upon addition of increasing molar
ratios of NB-506, the Tm for the triplex transition is system-
atically increased up to a maximal shift of over 30‡C. In
marked contrast, melting of the duplex is largely una¡ected
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by addition of NB-506. Note in Fig. 1 that NB-506 binds very
poorly to poly dA:poly dT. The melting studies are fully
consistent with the results obtained with the competition dial-
ysis method. Poor NB-506 binding to poly dA:poly dT is also
consistent with the results of recent DNase I footprinting
studies [14].
A variety of compounds has now been discovered that bind
with some preference to triplex DNA [26^28]. Competition
dialysis results were recently presented for some triplex selec-
tive compounds [20]. The relative preference for triplex exhib-
ited by NB-506 compares favorably with that shown by the
compounds BePI and coralyne, and its a¡ect on triplex melt-
ing is similar. The compound berberine was discovered to be
more triplex selective that either BePI or coralyne in the com-
petition dialysis procedure. Both NB-506 and berberine dra-
matically stabilize triplex DNA against thermal denaturation,
but have essentially no e¡ect on the melting of duplex. Com-
paratively, the overall binding of NB-506 to all forms of
nucleic acid was observed to be weaker than was observed
for BePI, coralyne and berberine, consistent with its compar-
atively smaller duplex DNA binding constant [14]. The weak-
er a⁄nity of NB-506 must arise, in part, from its lack of
charge, and consequently a near zero contribution to the bind-
ing free energy from the polyelectrolyte e¡ect [29,30]. To our
knowledge, the data of Figs. 1 and 2 represent the ¢rst dem-
onstration of the binding of an uncharged ligand to triplex
DNA.
Inspection of the structure of NB-506 reveals a region ho-
mologous with large portions of BePI, a compound known to
bind preferentially to triplex DNA. Fig. 3 shows an overlay of
the structures of NB-506 and BePI, showing the region of
maximal homology. The crescent shaped fragment common
to both compounds represents a potential pharmacophore for
selective triplex binding. Rigorous development of this phar-
macophore hypothesis will, of course, require much more ex-
tensive testing of a large number of additional compounds
Fig. 1. Top: Structure of NB-506. Bottom: Results of competition
dialysis experiment using NB-506. The amount of NB-506 bound to
the various nucleic acid structures listed in the table is shown as a
bar graph. The free ligand concentration in the experiment was
1 WM, and the total concentration of each nucleic acid conformational
form was 75 WM (in terms of the monomeric unit of each polymer).
Fig. 2. Results of thermal denaturation studies of the triplex poly
dA:(poly dT)2 in the presence of NB-506. Top: Di¡erential UV
melting curves are shown at di¡erent molar ratios of added NB-
506. The molar ratios (NB-506/triplet) for the curves are: a: 0; b:
0.1; c: 0.2; d: 0.5; e: 1.0 and f: 2.2. In the absence of NB-506, the
triplexCduplex+poly dT transition is centered at Tm = 42.5‡C.
Melting of the poly dA:poly dT duplex is centered at Tm = 75.2‡C.
NB-506 increases the triplex melting transition, but has little e¡ect
on duplex melting. All of the curves for duplex melting in the pres-
ence of NB-506 very nearly superimpose, and are centered around
75‡C. Bottom: Plot of vTm (the di¡erence in the apparent Tm in
the presence and absence of added NB-506) versus the molar ratio
of added NB-506. Data for triplex melting are shown as the solid
circles, while open circles show data for duplex melting.
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containing the molecular fragment. The ease and speed of the
competition dialysis approach will facilitate that testing pro-
cess.
It is of interest to note that the known triplex binders BePI
and coralyne also function as weak topoisomerase I inhibitors
[31,32]. The basis of a possible correlation between triplex
binding and topoisomerase I inhibitions is certainly unclear.
Perhaps the inhibitor binding site within the DNA-topo-
isomerase I complex shares structural similarities to triplex
DNA.
If the homologous structural fragment within NB-506
shown in Fig. 3 intercalates into triplex DNA in a manner
similar to the binding mode of BePI, we can speculate that
NB-506 binding would be stabilized by additional molecular
interactions of its carbohydrate moiety within one of the
grooves found in the triplex structure. We previously have
determined that the carbohydrate contributes 1.5 kcal mol31
to the DNA binding free energy of rebeccamycin (the parent
molecule of NB-506) [7]. A similar favorable contribution to
NB-506 binding to triplex would not be unreasonable.
The competition dialysis method yields additional signi¢-
cant information about the interaction of NB-506 with nucleic
acids. Its binding to natural DNA samples (Fig. 1) reveals a
positive correlation between the amount of NB-506 bound
and the GC content of the DNA. That observation is a clear
demonstration of preferential binding to GC base pairs. In
previous DNase I footprinting studies, we observed preferen-
tial binding of NB-506 to GC and GT dinucleotide sites [14].
The competition dialysis results independently con¢rm such a
GC preference.
Little or no binding to single-stranded DNA or to left-
handed Z DNA was observed. Previous linear dichroism stud-
ies demonstrated the NB-506 intercalated into a variety of
right-handed duplex DNA samples [14]. Single-stranded
DNA would not o¡er an appropriate intercalation site.
Lack of binding to left-handed Z DNA would be consistent
with the behavior of many intercalators, which inevitably
show a strong preference for right-handed, B form DNA
[33^35].
Finally, we note that NB-506 interacts to some extent with
RNA (as represented by poly A:poly U) and with a parallel-
stranded tetraplex DNA, (5P T2G20T2)4. The strength of these
interactions is comparable to that observed for the interaction
of NB-506 with duplex calf thymus DNA.
NB-506 is a potent topoisomerase I inhibitor [12]. The
structural preferences demonstrated here by the competition
dialysis method might be unrelated to the mechanism by
which NB-506 inhibits the enzyme. The mechanisms of action
of most anticancer agents are pleiotropic, and no single mech-
anism can in general account for all aspects of a given agent’s
cytotoxicity. A variety of experimental approaches has been
used to show that triplex DNA exists in the cell [36]. While
the biological role of triplex DNA in vivo is not clear, a
variety of models was proposed for its use as a regulatory
element in transcription or replication [36]. Our data suggests
that triplex DNA would represent an additional target for
NB-506, although such interactions may not be associated
with the drug’s e¡ect on tumor cells.
Acknowledgements: Supported by Grant CA35635 from the National
Cancer Institute (J.B.C.).
References
[1] Wakelin, L.P.G., and Waring, M.J. (1990) in: Comprehensive
Medicinal Chemistry (Sammes, P.G., Ed.), pp 703^724, Perga-
mon Press, Oxford.
[2] Wilson, W.D. (1998) in: DNA and Aspects of Molecular Biology
(Kool, E., Ed.).
[3] Kojiri, K., Kondo, H., Yoshinari, T., Arakawa, H., Nakajima,
S., Satoh, F., Kawamura, K., Okura, A., Suda, H. and Okanishi,
M. (1991) J. Antibiot. (Tokyo) 44, 723^728.
[4] Bush, J.A., Long, B.H., Catino, J.J., Bradner, W.T. and Tomita,
K. (1987) J. Antibiot. (Tokyo) 40, 668^678.
[5] Arakawa, H., Iguchi, T., Morita, M., Yoshinari, T., Kojiri, K.,
Suda, H., Okura, A. and Nishimura, S. (1995) Cancer Res. 55,
1316^1320.
[6] Bailly, C., Riou, J.F., Colson, P., Houssier, C., Rodrigues-Per-
eira, E. and Prudhomme, M. (1997) Biochemistry 36, 3917^3929.
[7] Bailly, C., Qu, X., Graves, D.E., Prudhomme, M. and Chaires,
J.B. (1999) Chem. Biol. 6, 277^286.
[8] Arakawa, H., Matsumoto, H., Morita, M., Sasaki, M., Taguchi,
K., Okura, A. and Nishimura, S. (1996) Jpn. J. Cancer Res. 87,
518^523.
[9] Kanzawa, F., Nishio, K., Kubota, N. and Saijo, N. (1995) Can-
cer Res. 55, 2806^2813.
[10] Vanhoefer, U., Voigt, W., Hilger, R.A., Yin, M.B., Harstrick, A.,
Seeber, S. and Rustum, Y.M. (1997) Oncol. Res. 9, 485^494.
[11] Saijo, N. (1998) Chest 113, 17S^23S.
[12] Yoshinari, T., Matsumoto, M., Arakawa, H., Okada, H., Nogu-
chi, K., Suda, H., Okura, A. and Nishimura, S. (1995) Cancer
Res. 55, 1310^1315.
[13] Pommier, Y., Pourquier, P., Fan, Y. and Strumberg, D. (1998)
Biochim. Biophys. Acta 1400, 83^105.
[14] Bailly, C., Qu, X., Chaires, J.B., Colson, P., Houssier, C., Ohku-
bo, M., Nishimura, S. and Yoshinari, T. (1999) J. Med. Chem.
42, 2927^2935.
[15] Thuong, N.T. and Helene, C. (1993) Angew. Chemi. Int. Edn. 32,
666^690.
[16] Haq, I., Ladbury, J.E., Chowdhry, B.Z. and Jenkins, T.C. (1996)
J. Am. Chem. Soc. 118, 10693^10701.
Fig. 3. Identi¢cation of a potential triplex pharmacophore for tri-
plex binding. The top image shows NB-506 (white) overlaid upon
the structure of the known triplex binding agent BePI (gray). The
region of maximal overlap is shown in black, and represents a po-
tential pharmacophore for triplex binding. The bottom pair of im-
ages shows the structures of the two compounds in isolation with
the common structural feature highlighted in black.
FEBS 23474 23-3-00
J. Ren et al./FEBS Letters 470 (2000) 355^359358
[17] Fedoro¡, O.Y., Salazar, M., Han, H., Chemeris, V.V., Kerwin,
S.M. and Hurley, L.H. (1998) Biochemistry 37, 12367^12374.
[18] Wheelhouse, R.T., Sun, D., Han, H., Han, F.X. and Hurley,
L.H. (1998) J. Am. Chem. Soc. 120, 3261^3262.
[19] Haq, I., Trent, J.O., Chowdhry, B.Z. and Jenkins, T.C. (1999)
J. Am. Chem. Soc. 121, 1768^1779.
[20] Ren, J. and Chaires, J.B. (1999) Biochemistry 38, 16067^16075.
[21] Muller, W. and Crothers, D.M. (1975) Eur. J. Biochem. 54, 267^
277.
[22] Chaires, J.B. (1992) in: Advances in DNA Sequence Speci¢c
Agents (Hurley, L.H., Ed.), pp 3^23, JAI Press, Greenwich, CT.
[23] Ohkubo, M., Kawamoto, H., Ohno, T., Nakano, M. and Mor-
ishima, H. (1997) Tetrahedron 53, 585^592.
[24] Chaires, J.B., Dattagupta, N. and Crothers, D.M. (1982) Bio-
chemistry 21, 3933^3940.
[25] Moller, A., Nordheim, A., Kozlowski, S.A., Patel, D.J. and Rich,
A. (1984) Biochemistry 23, 54^62.
[26] Wilson, W.D., Mizan, S., Tanious, F.A., Yao, S. and Zon, G.
(1994) J. Mol. Recognit. 7, 89^98.
[27] Shafer, R.H. (1998) Prog. Nucleic Acids Res. Mol. Biol. 59, 55^
94.
[28] Mergny, J.L., Duval-Valentin, G., Nguyen, C.H., Perrouault, L.,
Faucon, B., Rougee, M., Montenay-Garestier, T., Bisagni, E.
and Helene, C. (1992) Science 256, 1681^1684.
[29] Chaires, J.B. (1996) Anticancer Drug Des. 11, 569^580.
[30] Chaires, J.B. (1997) Biopolymers 44, 201^215.
[31] Gatto, B., Sanders, M.M., Yu, C., Wu, H.Y., Makhey, D., La-
Voie, E.J. and Liu, L.F. (1996) Cancer Res. 56, 2795^2800.
[32] Nguyen, C.H., Fan, E., Riou, J.F., Bissery, M.C., Vrignaud, P.,
Lavelle, F. and Bisagni, E. (1995) Anticancer Drug Des. 10, 277^
297.
[33] Chaires, J.B. (1986) J. Biol. Chem. 261, 8899^8907.
[34] Walker, G.T., Stone, M.P. and Krugh, T.R. (1985) Biochemistry
24, 7462^7471.
[35] Walker, G.T., Stone, M.P. and Krugh, T.R. (1985) Biochemistry
24, 7471^7479.
[36] Soyfer, V.N. and Potaman, V.N. (1996) Triple-Helical Nucleic
Acids, Springer, New York.
FEBS 23474 23-3-00
J. Ren et al./FEBS Letters 470 (2000) 355^359 359
